Eton Pharmaceuticals (ETON) Competitors

$29.54 -0.11 (-0.35%)

As of 02:53 PM Eastern

ETON vs. EWTX, NAMS, RCUS, ALMS, and BEAM

Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Edgewise Therapeutics (EWTX), NewAmsterdam Pharma (NAMS), Arcus Biosciences (RCUS), Alumis (ALMS), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Eton Pharmaceuticals (NASDAQ:ETON) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Edgewise Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -5.75%. Eton Pharmaceuticals' return on equity of -2.60% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-5.75%	-2.60%	-0.66%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Eton Pharmaceuticals presently has a consensus price target of $39.33, suggesting a potential upside of 33.13%. Edgewise Therapeutics has a consensus price target of $39.67, suggesting a potential upside of 15.18%. Given Eton Pharmaceuticals' higher possible upside, equities analysts plainly believe Eton Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Edgewise Therapeutics had 9 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 11 mentions for Edgewise Therapeutics and 2 mentions for Eton Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 0.67 beat Eton Pharmaceuticals' score of 0.25 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eton Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.

Eton Pharmaceuticals has higher revenue and earnings than Edgewise Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	10.11	-$4.60M	-$0.18	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Summary

Eton Pharmaceuticals and Edgewise Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to NewAmsterdam Pharma?

Eton Pharmaceuticals (NASDAQ:ETON) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Eton Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	10.11	-$4.60M	-$0.18	N/A
NewAmsterdam Pharma	$22.50M	203.84	-$203.82M	-$1.79	N/A

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eton Pharmaceuticals has a net margin of -5.75% compared to NewAmsterdam Pharma's net margin of -943.23%. Eton Pharmaceuticals' return on equity of -2.60% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-5.75%	-2.60%	-0.66%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

In the previous week, NewAmsterdam Pharma had 12 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 14 mentions for NewAmsterdam Pharma and 2 mentions for Eton Pharmaceuticals. NewAmsterdam Pharma's average media sentiment score of 0.69 beat Eton Pharmaceuticals' score of 0.25 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Eton Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.

Eton Pharmaceuticals currently has a consensus price target of $39.33, suggesting a potential upside of 33.13%. NewAmsterdam Pharma has a consensus price target of $48.00, suggesting a potential upside of 20.32%. Given Eton Pharmaceuticals' higher probable upside, research analysts clearly believe Eton Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Eton Pharmaceuticals beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Arcus Biosciences?

Eton Pharmaceuticals (NASDAQ:ETON) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Eton Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	10.11	-$4.60M	-$0.18	N/A
Arcus Biosciences	$236M	13.43	-$353M	-$3.18	N/A

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eton Pharmaceuticals has a net margin of -5.75% compared to Arcus Biosciences' net margin of -156.36%. Eton Pharmaceuticals' return on equity of -2.60% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-5.75%	-2.60%	-0.66%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

In the previous week, Arcus Biosciences had 24 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 26 mentions for Arcus Biosciences and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.25 beat Arcus Biosciences' score of 0.12 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Eton Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Eton Pharmaceuticals currently has a consensus price target of $39.33, suggesting a potential upside of 33.13%. Arcus Biosciences has a consensus price target of $33.33, suggesting a potential upside of 32.25%. Given Eton Pharmaceuticals' higher probable upside, research analysts clearly believe Eton Pharmaceuticals is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Arcus Biosciences beats Eton Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Alumis?

Alumis (NASDAQ:ALMS) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 40.7% of Alumis shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eton Pharmaceuticals has a net margin of -5.75% compared to Alumis' net margin of -1,011.75%. Eton Pharmaceuticals' return on equity of -2.60% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-1,011.75%	-116.97%	-88.43%
Eton Pharmaceuticals	-5.75%	-2.60%	-0.66%

In the previous week, Alumis and Alumis both had 2 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.25 beat Alumis' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eton Pharmaceuticals has higher revenue and earnings than Alumis. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	128.07	-$243.32M	-$3.06	N/A
Eton Pharmaceuticals	$79.95M	10.11	-$4.60M	-$0.18	N/A

Alumis currently has a consensus price target of $38.60, indicating a potential upside of 59.41%. Eton Pharmaceuticals has a consensus price target of $39.33, indicating a potential upside of 33.13%. Given Alumis' stronger consensus rating and higher possible upside, equities analysts clearly believe Alumis is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alumis has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

Eton Pharmaceuticals beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Beam Therapeutics currently has a consensus price target of $47.17, indicating a potential upside of 44.24%. Eton Pharmaceuticals has a consensus price target of $39.33, indicating a potential upside of 33.13%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Beam Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Eton Pharmaceuticals has a net margin of -5.75% compared to Beam Therapeutics' net margin of -39.66%. Eton Pharmaceuticals' return on equity of -2.60% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Eton Pharmaceuticals	-5.75%	-2.60%	-0.66%

In the previous week, Beam Therapeutics had 8 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 10 mentions for Beam Therapeutics and 2 mentions for Eton Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.57 beat Eton Pharmaceuticals' score of 0.25 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eton Pharmaceuticals has lower revenue, but higher earnings than Beam Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$164.01M	20.48	-$79.99M	-$0.68	N/A
Eton Pharmaceuticals	$79.95M	10.11	-$4.60M	-$0.18	N/A

Beam Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

Beam Therapeutics beats Eton Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$808.35M	$3.38B	$6.20B	$12.30B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-164.13	15.24	20.71	25.86
Price / Sales	10.11	281.71	549.99	74.51
Price / Cash	N/A	56.93	27.81	36.27
Price / Book	30.15	7.00	9.82	6.79
Net Income	-$4.60M	$24.11M	$3.55B	$333.31M
7 Day Performance	N/A	N/A	N/A	0.56%
1 Month Performance	12.08%	5.45%	6.77%	9.42%
1 Year Performance	75.13%	79.61%	42.65%	43.23%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	3.7629 of 5 stars	$29.55 -0.4%	$39.33 +33.1%	+75.8%	$808.35M	$79.95M	N/A	20	Upcoming Earnings
EWTX Edgewise Therapeutics	1.6722 of 5 stars	$31.45 +2.7%	$38.13 +21.2%	+142.2%	$3.29B	N/A	N/A	60	Earnings Report
NAMS NewAmsterdam Pharma	3.3961 of 5 stars	$29.86 +5.0%	$48.00 +60.8%	+110.8%	$3.27B	$22.50M	N/A	4	News Coverage Earnings Report Analyst Upgrade Gap Down
RCUS Arcus Biosciences	2.4503 of 5 stars	$26.05 +1.4%	$32.44 +24.5%	+206.4%	$3.23B	$247M	N/A	500	Earnings Report Analyst Downgrade Analyst Revision
ALMS Alumis	2.0126 of 5 stars	$25.25 +0.3%	$38.60 +52.9%	+370.4%	$3.20B	$24.05M	N/A	N/A	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. EWTX, NAMS, RCUS, ALMS, and BEAM

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Eton Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

How does Eton Pharmaceuticals compare to Arcus Biosciences?

Summary

How does Eton Pharmaceuticals compare to Alumis?

Summary

How does Eton Pharmaceuticals compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. EWTX, NAMS, RCUS, ALMS, and BEAM

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Is ETON or EWTX more profitable?

Do analysts recommend ETON or EWTX?

Does the media refer more to ETON or EWTX?

Do institutionals and insiders hold more shares of ETON or EWTX?

Which has more risk & volatility, ETON or EWTX?

Which has better valuation and earnings, ETON or EWTX?

Summary

How does Eton Pharmaceuticals compare to NewAmsterdam Pharma?

Which has preferable valuation & earnings, ETON or NAMS?

Do insiders & institutionals hold more shares of ETON or NAMS?

Is ETON or NAMS more profitable?

Does the media prefer ETON or NAMS?

Which has more volatility and risk, ETON or NAMS?

Do analysts prefer ETON or NAMS?

Summary

How does Eton Pharmaceuticals compare to Arcus Biosciences?

Which has preferable valuation & earnings, ETON or RCUS?

Do insiders & institutionals hold more shares of ETON or RCUS?

Is ETON or RCUS more profitable?

Does the media prefer ETON or RCUS?

Which has more volatility and risk, ETON or RCUS?

Do analysts prefer ETON or RCUS?

Summary

How does Eton Pharmaceuticals compare to Alumis?

Do institutionals & insiders hold more shares of ALMS or ETON?

Is ALMS or ETON more profitable?

Does the media favor ALMS or ETON?

Which has higher earnings and valuation, ALMS or ETON?

Do analysts rate ALMS or ETON?

Which has more risk & volatility, ALMS or ETON?

Summary

How does Eton Pharmaceuticals compare to Beam Therapeutics?

Do analysts rate BEAM or ETON?

Is BEAM or ETON more profitable?

Does the media favor BEAM or ETON?

Do institutionals & insiders hold more shares of BEAM or ETON?

Which has higher earnings and valuation, BEAM or ETON?

Which has more risk & volatility, BEAM or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools